Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
Do‐Youn Oh, Aiwu Ruth He, Shukui Qin, Li‐Tzong Chen, Takuji Okusaka, Jin Won Kim, Thatthan Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, Howard A. Burris, Mohamed Bouattour, Suebpong Tanasanvimon, Renata Zaucha, Antonio Avallone, Juan Cundom, A. Kuzko, Julie Wang, Ioannis Xynos, Arndt Vogel, Juan W. Valle
Topics & Concepts
DurvalumabBiliary tract cancerMedicineTopazBiliary tractChemotherapyCancerOncologyInternal medicineGemcitabineBiologyNivolumabImmunotherapyPaleontologyCholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct DisordersLiver Diseases and Immunity